Micafungin in pediatric and adolescent patients;Utilidad clínica de la micafungina en el niño y el adolescente

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 62-64

  Madero López, Luis ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Antifungal; Aspergillus; Candida; Equinocandinas; Micafungina Pediatric

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NIFEDIPINE; POSACONAZOLE; RAPAMYCIN; STEROID; TACROLIMUS; VORICONAZOLE;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL WALL; CHILD; CHILD HEALTH CARE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; FUNGAL CELL; HUMAN; HYPERBILIRUBINEMIA; INVASIVE CANDIDIASIS; MAXIMUM PLASMA CONCENTRATION; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRESCHOOL CHILD; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; SCHOOL CHILD; SIDE EFFECT;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGEMIA; HUMANS; INFANT; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS;

ASPERGILLUS; CANDIDA;

EID: 67650725748     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70010-5     Document Type: Review

References (21)

1. Arrieta A.C., Seibel N., and Kovanda L. Safety, efficacy and pharmacokinetics of micafungin in pediatric patients. 46th Interscience Conference on Antimicrobiol Agents and Chemotherapy. San Francisco (2006) Abstract M-876
2. Ashouri N., Singh J., and Arrieta A. Micafungin in pediatrics: when one size does not fit all. Exp Opin Drug Metab Toxicol 4 (2008) 463-469
3. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
4. Douglas C.M. Fungal beta (1,3)-D-Glucan sintesis. Med Mycol 39 (2001) 55-66
5. Flynn P., Seibel N., and Arrieta A.C. Treatment of invasive aspergillosis in pediatric patients with micafungin alone or in combination with other sistemic antifungal agents. 46th Interscience Conference on Antimicrobial Agents and chemotherapy. San Francisco (2006) Abstract M-891
6. Ghannoum M.A., and Rice L.B. Antifungal agents: mode of action, mechanisms of resistence, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 (1999) 501-517
7. Heresi G.P., Gerestmann D.R., Reed M.D., Van den Anker J.N., Blumer J.L., Kovanda L., Keirns J.J., Buell D.N., and Kearns G.L. The pharmacokinetics and safety of micafungin, a novel echinocadin, in premature infants. Pediatric Infect Dis J 25 (2006) 1110-1115
8. Nakai T., Uno J., Ikeda F., Tawara S., Nishimura K., and Miyaki M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antiminob Agents Chemother 47 (2003) 1376-1381
9. Natafajan G., Lulic-Botica M., Rongkavilit C., Pappas A., and Bedard M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 25 (2005) 770-777
10. Odio C.D., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., Saenz A., Herrera M.L., and Walsh T.J. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 23 (2004) 1093-1097
11. Ostrosky-Zeichner L., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hylop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2000 blood stream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
12. Ostrosky-Zeichner L., Kontoyiannis D., Raffali J., Mullane K.M., Vazquez J., Anaissie E.J., Lipton J., Jacobs P., van Rensburg J.H., Rex J.H., Lau W., Fcklam D., and Buell D.N. International open-label, noncomparative, clinical trial of micafungin alone and in combination with other sistemic antifungal agents. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661
13. Queiroz-Telles F., Berezin E., Leverger G., Freire A., Van der Vyver A., and Konja J. Micanfungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis. Pediatric Infect Dis 27 (2008) 820-826
14. Roilides E., Farmaki E., Evdosidou J., Dotis J., Hatziloannnidis E., Tsivitanidou M., Bibashi E., Filioti I., Sofianou D., Gil-Lamaignere C., Mueller F.M., and Kremenopoulos G. Neonatal candidiasis: analysis of epidemiology, drug susceptibility and molecular typing of curative isolates. Eur J Clin Microbil Infect Dis 64 (2004) 1997-2020
15. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., Keirns J., Lau W.M., Facklam D.P., Buell D.N., and Walsh T.J. Safety, tolerability and pharmacokinetics of micafungin (FK 463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49 (2005) 3317-3324
16. Sobel J.D. Practice guidelines for the treatment of fungal infectious. Clin Infect Dis 30 (2000) 652-653
17. Steinbach W.J. Pediatric aspergillosis: disease and treatment differences in children. Pediatr Infect Dis J 24 (2005) 358-364
18. Takakura S., Fujihara N.K., Saito T., Kudo T., Tinuma Y., and Ichiyama S. National surveillance os species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53 (2004) 283-289
19. Van Burik J.A., Ratanatharathorn V., Stephan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., and Walsh T.J. Micafungin versus/fluconazole for prophylasis against invasive fungal infectious during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
20. Vescan I., Ketko A.K., and Sobel J. Spontaeus in vitro resistance to echinocandins among Candida parapsilopsis and Candida albicans isolates. 47th Interscience. Conference Antimicrobiol Agents and Chemotherapy. Chicago (2007) Abstract M-532
21. Wiederhold N.P., and Lewis R.E. The echinocandin antifungals: an overview of the pharmacology spectrum and clinical efficay. Exp Opin Investig Drugs 12 (2003) 1313-1333